Unravelling the determinants of human health in French Polynesia: the MATAEA project.

French Polynesia communicable diseases cross-sectional survey non-communicable diseases population genetics

Journal

Frontiers in epidemiology
ISSN: 2674-1199
Titre abrégé: Front Epidemiol
Pays: Switzerland
ID NLM: 9918419158106676

Informations de publication

Date de publication:
2023
Historique:
received: 05 04 2023
accepted: 15 08 2023
medline: 8 3 2024
pubmed: 8 3 2024
entrez: 8 3 2024
Statut: epublish

Résumé

French Polynesia is a French overseas collectivity in the Southeast Pacific, comprising 75 inhabited islands across five archipelagoes. The human settlement of the region corresponds to the last massive migration of humans to empty territories, but its timeline is still debated. Despite their recent population history and geographical isolation, inhabitants of French Polynesia experience health issues similar to those of continental countries. Modern lifestyles and increased longevity have led to a rise in non-communicable diseases (NCDs) such as obesity, diabetes, hypertension, and cardiovascular diseases. Likewise, international trade and people mobility have caused the emergence of communicable diseases (CDs) including mosquito-borne and respiratory diseases. Additionally, chronic pathologies including acute rheumatic fever, liver diseases, and ciguatera, are highly prevalent in French Polynesia. However, data on such diseases are scarce and not representative of the geographic fragmentation of the population. The present project aims to estimate the prevalence of several NCDs and CDs in the population of the five archipelagoes, and identify associated risk factors. Moreover, genetic analyses will contribute to determine the sequence and timings of the peopling history of French Polynesia, and identify causal links between past genetic adaptation to island environments, and present-day susceptibility to certain diseases. This cross-sectional survey is based on the random selection of 2,100 adults aged 18-69 years and residing on 18 islands from the five archipelagoes. Each participant answered a questionnaire on a wide range of topics (including demographic characteristics, lifestyle habits and medical history), underwent physical measurements (height, weight, waist circumference, arterial pressure, and skin pigmentation), and provided biological samples (blood, saliva, and stool) for biological, genetic and microbiological analyses. For the first time in French Polynesia, the present project allows to collect a wide range of data to explore the existence of indicators and/or risk factors for multiple pathologies of public health concern. The results will help health authorities to adapt actions and preventive measures aimed at reducing the incidence of NCDs and CDs. Moreover, the new genomic data generated in this study, combined with anthropological data, will increase our understanding of the peopling history of French Polynesia. https://clinicaltrials.gov/, identifier: NCT06133400.

Sections du résumé

Background UNASSIGNED
French Polynesia is a French overseas collectivity in the Southeast Pacific, comprising 75 inhabited islands across five archipelagoes. The human settlement of the region corresponds to the last massive migration of humans to empty territories, but its timeline is still debated. Despite their recent population history and geographical isolation, inhabitants of French Polynesia experience health issues similar to those of continental countries. Modern lifestyles and increased longevity have led to a rise in non-communicable diseases (NCDs) such as obesity, diabetes, hypertension, and cardiovascular diseases. Likewise, international trade and people mobility have caused the emergence of communicable diseases (CDs) including mosquito-borne and respiratory diseases. Additionally, chronic pathologies including acute rheumatic fever, liver diseases, and ciguatera, are highly prevalent in French Polynesia. However, data on such diseases are scarce and not representative of the geographic fragmentation of the population.
Objectives UNASSIGNED
The present project aims to estimate the prevalence of several NCDs and CDs in the population of the five archipelagoes, and identify associated risk factors. Moreover, genetic analyses will contribute to determine the sequence and timings of the peopling history of French Polynesia, and identify causal links between past genetic adaptation to island environments, and present-day susceptibility to certain diseases.
Methods UNASSIGNED
This cross-sectional survey is based on the random selection of 2,100 adults aged 18-69 years and residing on 18 islands from the five archipelagoes. Each participant answered a questionnaire on a wide range of topics (including demographic characteristics, lifestyle habits and medical history), underwent physical measurements (height, weight, waist circumference, arterial pressure, and skin pigmentation), and provided biological samples (blood, saliva, and stool) for biological, genetic and microbiological analyses.
Conclusion UNASSIGNED
For the first time in French Polynesia, the present project allows to collect a wide range of data to explore the existence of indicators and/or risk factors for multiple pathologies of public health concern. The results will help health authorities to adapt actions and preventive measures aimed at reducing the incidence of NCDs and CDs. Moreover, the new genomic data generated in this study, combined with anthropological data, will increase our understanding of the peopling history of French Polynesia.
Clinical trial registration UNASSIGNED
https://clinicaltrials.gov/, identifier: NCT06133400.

Identifiants

pubmed: 38455935
doi: 10.3389/fepid.2023.1201038
pmc: PMC10911015
doi:

Banques de données

ClinicalTrials.gov
['NCT06133400']

Types de publication

Journal Article

Langues

eng

Pagination

1201038

Informations de copyright

© 2023 Teiti, Aubry, Fernandes-Pellerin, Patin, Madec, Boucheron, Vanhomwegen, Torterat, Lastère, Olivier, Jaquaniello, Roux, Mendiboure, Harmant, Bisiaux, Rijo de León, Liu, Bossin, Mathieu-Daudé, Gatti, Suhas, Chung, Condat, Ayotte, Conte, Jolly, Manuguerra, Sakuntabhai, Fontanet, Quintana-Murci and Cao-Lormeau.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Iotefa Teiti (I)

Laboratory of Research on Emerging Viral Diseases, Institut Louis Malardé, Papeete, French Polynesia.

Maite Aubry (M)

Laboratory of Research on Emerging Viral Diseases, Institut Louis Malardé, Papeete, French Polynesia.

Sandrine Fernandes-Pellerin (S)

Center for Translational Sciences, Institut Pasteur, Paris, France.

Etienne Patin (E)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.

Yoann Madec (Y)

Institut Pasteur, Université Paris Cité, Epidemiology of Emerging Diseases Unit, Paris, France.

Pauline Boucheron (P)

Institut Pasteur, Université Paris Cité, Epidemiology of Emerging Diseases Unit, Paris, France.

Jessica Vanhomwegen (J)

Environment and Infectious Risk Unit, Laboratory for Urgent Response to Biological Threats, Institut Pasteur, Paris, France.

Jérémie Torterat (J)

Institut de la Statistique de la Polynésie Française, Papeete, French Polynesia.

Stéphane Lastère (S)

Clinical Laboratory, Centre Hospitalier de la Polynésie Française, Pirae, French Polynesia.

Sophie Olivier (S)

Clinical Laboratory, Institut Louis Malardé, Papeete, French Polynesia.

Anthony Jaquaniello (A)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.
Institut Pasteur, Data Management Core Facility, Paris, France.

Maguelonne Roux (M)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.
Institut Pasteur, Université de Paris, Bioinformatics and Biostatistics Hub, Paris, France.

Vincent Mendiboure (V)

Institut Pasteur, Université Paris Cité, Epidemiology of Emerging Diseases Unit, Paris, France.

Christine Harmant (C)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.

Aurélie Bisiaux (A)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.

Gaston Rijo de León (G)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.

Dang Liu (D)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.

Hervé Bossin (H)

Laboratory of Research in Medical Entomology, Institut Louis Malardé, Paea, French Polynesia.

Françoise Mathieu-Daudé (F)

Laboratory of Research in Medical Entomology, Institut Louis Malardé, Paea, French Polynesia.
UMR MIVEGEC-Infectious Diseases and Vectors, University of Montpellier, CNRS, IRD, Montpellier, France.

Clémence Gatti (C)

Laboratory of Marine Biotoxins, UMR241-Ecosystèmes Insulaires Océaniens (EIO) (IFREMER, ILM, IRD, UPF), Institut Louis Malardé, Papeete, French Polynesia.

Edouard Suhas (E)

Unit on non-Communicable Diseases, UMR241-Ecosystèmes Insulaires Océaniens (EIO) (IFREMER, ILM, IRD, UPF), Institut Louis Malardé, Papeete, French Polynesia.

Kiyojiken Chung (K)

Laboratory of Research on Emerging Viral Diseases, Institut Louis Malardé, Papeete, French Polynesia.

Bertrand Condat (B)

Department of Gastroenterology, Centre Hospitalier de la Polynésie Française, Pirae, French Polynesia.

Pierre Ayotte (P)

Centre de Toxicologie du Québec, Institut National de Santé Publique du Québec, QC, Canada.

Eric Conte (E)

Maison des Sciences de l'Homme du Pacifique, Université de la Polynésie Française, Punaauia, French Polynesia.

Nathalie Jolly (N)

Center for Translational Sciences, Institut Pasteur, Paris, France.

Jean-Claude Manuguerra (JC)

Environment and Infectious Risk Unit, Laboratory for Urgent Response to Biological Threats, Institut Pasteur, Paris, France.

Anavaj Sakuntabhai (A)

Functional Genetics of Infectious Diseases Unit, Department of Global Health, Institut Pasteur, Paris, France.

Arnaud Fontanet (A)

Institut Pasteur, Université Paris Cité, Epidemiology of Emerging Diseases Unit, Paris, France.
PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.

Lluis Quintana-Murci (L)

Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, Paris, France.
Chair Human Genomics and Evolution, Collège de France, Paris, France.

Van-Mai Cao-Lormeau (VM)

Laboratory of Research on Emerging Viral Diseases, Institut Louis Malardé, Papeete, French Polynesia.

Classifications MeSH